Niva Bupa Health

Why is Niva Bupa Health Insurance Company Ltd falling/rising?

As of 25-Aug, Niva Bupa Health Insurance Company Ltd's stock price is rising due to strong financial growth, increased investor participation, and high institutional confidence, with a current price of 83.15 and a 0.7% increase. The company has shown impressive long-term performance, including a 410.9% growth in profit after tax for the latest quarter.

As of 25-Aug, Niva Bupa Health Insurance Company Ltd's stock price is rising, currently at 83.15, with a change of 0.58 (0.7%) upward. This increase can be attributed to several positive factors highlighted in the source data. <BR><BR>Firstly, the company has demonstrated strong long-term fundamental strength, evidenced by a remarkable 137.70% compound annual growth rate (CAGR) in operating profits and a 43.20% annual growth rate in net sales. Additionally, the positive financial results reported for the quarter ending June 26 show a significant growth in profit after tax (PAT) of 410.9% compared to the previous four-quarter average, alongside a 34.2% increase in net sales.<BR><BR>Moreover, there has been a notable rise in investor participation, with a delivery volume of 6.78 lacs on August 24, which is a 64.43% increase against the five-day average. This suggests growing interest and confidence among investors in the stock. The stock is also performing in line with its sector, which may further bolster investor sentiment.<BR><BR>Furthermore, the company has high institutional holdings at 28.25%, indicating that institutional investors, who typically have more resources to analyze company fundamentals, are confident in the stock's potential. Their stake has increased by 1.16% over the previous quarter, reflecting a positive outlook on the company's future performance.<BR><BR>In summary, the combination of strong financial growth, increased investor participation, and high institutional confidence contributes to the rising stock price of Niva Bupa Health Insurance Company Ltd.

Which are the latest news on Niva Bupa Health?

What does Niva Bupa Health do?

Niva Bupa Health Insurance Company Ltd, originally Max Bupa, is a small-cap health insurance provider in India, reporting net sales of 2,274 Cr and a net profit of 138 Cr for June 2026. It has a market cap of INR 15,596 Cr, a P/E ratio of 90, and a return on equity of 4.61%.

Overview:<BR>Niva Bupa Health Insurance Company Ltd operates in the insurance industry and is categorized as a small-cap company.<BR><BR>History:<BR>The company was originally incorporated as Max Bupa Health Insurance Limited in 2008. It received its Certificate for Commencement of Business on December 23, 2008. The latest quarterly results reported are for June 2026, showing net sales and profit figures.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 2,274 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: 138 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 15,596 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 90.00 <BR>Industry P/E: 21 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.00 <BR>Return on Equity: 4.61% <BR>Price to Book: 4.09 <BR><BR>Contact Details:<BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Who are the peers of the Niva Bupa Health?

Niva Bupa Health's peers include HDFC Life, ICICI Lombard, ICICI Prudential Life, Max Financial, Star Health, New India Assurance, Go Digit General, and Medi Assist. Niva Bupa shows excellent growth but has an average management risk, with a 1-year return of 3.34%.

Peers: The peers of Niva Bupa Health are HDFC Life Insur., ICICI Lombard, ICICI Pru Life, General Insuranc, Max Financial, Star Health Insu, New India Assura, Go Digit General, and Medi Assist Ser.<BR><BR>Quality Snapshot: Excellent management risk is observed at ICICI Lombard and Medi Assist Ser., while Good management risk is found at Go Digit General. Average management risk is present in HDFC Life Insur., ICICI Pru Life, General Insuranc, Max Financial, Star Health Insu, and Niva Bupa Health, and the rest. Below Average management risk is noted at New India Assura. In terms of Growth, Excellent growth is seen at Niva Bupa Health, while Average growth is found at HDFC Life Insur., ICICI Lombard, General Insuranc, Go Digit General, and Medi Assist Ser., and the rest. Below Average growth is present in ICICI Pru Life, Max Financial, Star Health Insu, and New India Assura.<BR><BR>Return Snapshot: Star Health Insu has the highest 1-year return at 31.46%, while Medi Assist Ser. has the lowest at -36.68%. Niva Bupa Health's 1-year return is 3.34%, which is higher than Medi Assist Ser. but lower than Star Health Insu. Additionally, the six-month return is negative for HDFC Life Insur., ICICI Lombard, ICICI Pru Life, Max Financial, Go Digit General, and Medi Assist Ser.

How big is Niva Bupa Health?

As of 14th August, Niva Bupa Health Insurance Company Ltd has a market capitalization of 15,311.66 Cr and reported net sales of 7265.52 Cr and a net profit of 174.25 Cr over the latest four quarters.

As of 14th August, <BR><BR>Market Cap: Niva Bupa Health Insurance Company Ltd has a market capitalization of 15,311.66 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 7265.52 Cr, while the sum of Net Profit for the same period is 174.25 Cr.<BR><BR>Balance Sheet Snapshot: For the reporting period of March 2026, Shareholder's Funds are valued at 3,786.31 Cr, and Total Assets amount to 11,241.43 Cr.

Are Niva Bupa Health Insurance Company Ltd latest results good or bad?

Niva Bupa Health Insurance Company's Q1 FY27 results are generally positive, with a 92.93% year-on-year net profit increase to ₹137.80 crores and a 28.56% revenue growth. However, a 13.54% sequential profit decline and a below-average return on equity indicate areas for improvement.

Niva Bupa Health Insurance Company Ltd's latest results for Q1 FY27 can be considered good overall, despite some mixed signals. The company reported a net profit of ₹137.80 crores, which is a remarkable increase of 92.93% year-on-year. Additionally, revenue grew by 28.56% to ₹2,273.72 crores, indicating strong top-line momentum.<BR><BR>The operating margin improved to 8.10%, up from 5.55% in the same quarter last year, reflecting better operational efficiency and cost management. However, it's worth noting that the net profit decreased by 13.54% compared to the previous quarter, which raises some concerns about sequential performance.<BR><BR>While the company has demonstrated significant revenue growth and improved profitability metrics, its return on equity (ROE) of 4.56% remains below industry averages, indicating challenges in capital efficiency. This aspect could be a concern for investors looking for strong returns on their investments.<BR><BR>In summary, while Niva Bupa's quarterly results show strong growth and operational improvements, the decline in sequential profit and lower ROE suggest that there are still areas for the company to address. Overall, the results reflect a positive trajectory, but caution is warranted regarding sustainability and capital efficiency moving forward.

Should I buy, sell or hold Niva Bupa Health Insurance Company Ltd?

When is the next results date for Niva Bupa Health Insurance Company Ltd?

The next results date for Niva Bupa Health Insurance Company Ltd is July 30, 2026.

The next results date for Niva Bupa Health Insurance Company Ltd is scheduled for July 30, 2026.

Is Niva Bupa Health technically bullish or bearish?

As of November 28, 2025, Niva Bupa Health's technical stance is bearish due to negative indicators like a bearish MACD and moving averages, despite a mildly bullish signal from Dow Theory.

As of 28 November 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance for Niva Bupa Health is bearish, with a moderate strength. Key indicators driving this stance include the bearish MACD on the weekly timeframe, bearish signals from Bollinger Bands and moving averages on the daily timeframe, and a bearish KST on the weekly. Although the Dow Theory indicates a mildly bullish signal on the weekly, it is outweighed by the overall bearish indicators. The stock has underperformed against the Sensex year-to-date and over the past year, further supporting the bearish outlook.

How has been the historical performance of Niva Bupa Health?

Niva Bupa Health experienced significant growth from March 2024 to March 2025, with net sales rising to 4,894.46 Cr and profit after tax increasing to 213.52 Cr, while total assets grew to 9,760.16 Cr. The company improved its operating profit margin to 1.19% and enhanced cash flow from operating activities to 1,654.00 Cr.

Answer:<BR>The historical performance of Niva Bupa Health shows significant growth in various financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Niva Bupa Health's net sales increased from 3,811.25 Cr in March 2024 to 4,894.46 Cr in March 2025, while other operating income rose from 304.22 Cr to 479.82 Cr, leading to a total operating income of 5,374.28 Cr, up from 4,115.47 Cr. Total expenditure, excluding depreciation, also increased to 5,316.18 Cr from 4,254.40 Cr, with employee costs rising slightly and manufacturing expenses significantly increasing from 3,000.37 Cr to 4,061.10 Cr. The company turned around its operating profit, achieving 213.52 Cr in March 2025 compared to 81.85 Cr in March 2024, with a notable improvement in operating profit margin from -3.65% to 1.19%. Profit after tax also saw a substantial increase from 81.85 Cr to 213.52 Cr, resulting in a PAT margin growth from 2.15% to 4.36%. On the balance sheet, total assets grew from 6,191.86 Cr to 9,760.16 Cr, driven by an increase in non-current investments from 5,458.23 Cr to 8,175.08 Cr. Shareholder's funds rose significantly from 2,982.62 Cr to 3,776.22 Cr, while total liabilities increased to 9,760.16 Cr from 6,191.86 Cr. Cash flow from operating activities improved to 1,654.00 Cr from 812.00 Cr, although cash flow from investing activities worsened to -2,347.00 Cr from -1,881.00 Cr. The closing cash and cash equivalents increased to 220.00 Cr from 142.00 Cr, reflecting a positive cash flow trend.

Is Niva Bupa Health overvalued or undervalued?

As of November 27, 2024, Niva Bupa Health is considered very expensive and overvalued, with a PE ratio of 71.14 and significant underperformance at -0.62% year-to-date compared to the Sensex's 5.54%.

As of 27 November 2024, the valuation grade for Niva Bupa Health has moved from does not qualify to very expensive. The company is currently considered overvalued, with a PE ratio of 71.14, an EV to EBITDA ratio of 263.82, and a Price to Book Value of 7.37. These metrics significantly exceed those of its peers, such as Life Insurance with a PE ratio of 12.54 and Bajaj Finance Ltd. at 35.01, indicating a stark contrast in valuation.<BR><BR>In comparison to the broader market, Niva Bupa Health has underperformed, with a year-to-date return of -0.62% against the Sensex's 5.54%. This underperformance, coupled with its high valuation ratios, reinforces the conclusion that the company is overvalued in the current market environment.

Who are the top shareholders of the Niva Bupa Health?

The top shareholders of Niva Bupa Health are Bupa Singapore Holdings Pte Ltd with 55.98%, followed by foreign institutional investors at 8.9%, mutual funds at 2.68%, and individual investors at 4.23%. There are no pledged promoter holdings, reflecting strong promoter commitment.

The top shareholders of Niva Bupa Health include Bupa Singapore Holdings Pte Ltd, which holds a significant 55.98% of the company. The majority of the remaining shares are held by mutual funds, which account for 2.68% across 14 schemes, and foreign institutional investors (FIIs), who hold 8.9% through 42 different entities. Additionally, individual investors collectively own 4.23% of the shares. Notably, there are no pledged promoter holdings, indicating a strong commitment from the promoters.

Has Niva Bupa Health declared dividend?

No Dividend History Available